A Proven Combination For AAV Production

Viral vector-based therapeutics are expanding to target a wider range of indications beyond ultra-rare diseases. As a result, drug developers and manufacturers are looking for scalable, standardized, and robust production platforms. Learn about a combination of high-performing raw materials, advanced synthetic transfection reagents, and chemically defined HEK media that can be used to overcome the challenges of commercial-scale production.